Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 4/20 | 0.64 |
| ▸ | APP | P05067 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6101976 | 1.00 | SNCA (0.64) | SNCAAPPMAPTGAAALDH1A1 | |
| SCHEMBL6101360 | 0.83 | MAPT (0.56) | APPMAPTGAAALDH1A1TSHR | |
| SCHEMBL6101354 | 0.83 | MAPT (0.56) | APPMAPTGAAALDH1A1TSHR | |
| SCHEMBL6100790 | 0.79 | GAA (0.55) | MAPTGAAALDH1A1TSHRNFKB1 | |
| SCHEMBL6101314 | 0.78 | KMT2A (0.55) | MAPTGAAALDH1A1TSHRNFKB1 | |
| SCHEMBL6100957 | 0.76 | GAA (0.52) | MAPTGAAALDH1A1TSHRNFKB1 | |
| SCHEMBL27321163 | 0.76 | GAA (0.60) | GAAMEN1KMT2APOLBGFER | |
| SCHEMBL6100235 | 0.75 | BCHE (0.65) | MAPTGAAALDH1A1TSHRNFKB1 | |
| SCHEMBL6099937 | 0.75 | ALDH1A1 (0.65) | MAPTGAAALDH1A1TSHRNFKB1 | |
| SCHEMBL6101644 | 0.73 | SMN1; SMN2 (0.64) | MAPTGAAALDH1A1TSHRNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7084176-B2 | N-arylphenylacetamide derivatives and medicinal compositions containing the same | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2006-08-01 | — | — | US | disclosed |
| US-20040248983-A1 | N-arylphenylacetamide derivatives and medicinal compositions containing the same | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-12-09 | — | — | US | disclosed |
| EP-1403235-A1 | N-ARYLPHENYLACETAMIDE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | Dainippon Pharmaceutical Co., Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248983-A1 | N-arylphenylacetamide derivatives and medicinal compositions containing the same | HRH2, CCR8, CYP2C8 | SNCA 758/4885APP 4227/4885MAPT 4374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.